AU2019335366A1 - Imidazoquinoline compounds and uses thereof - Google Patents

Imidazoquinoline compounds and uses thereof Download PDF

Info

Publication number
AU2019335366A1
AU2019335366A1 AU2019335366A AU2019335366A AU2019335366A1 AU 2019335366 A1 AU2019335366 A1 AU 2019335366A1 AU 2019335366 A AU2019335366 A AU 2019335366A AU 2019335366 A AU2019335366 A AU 2019335366A AU 2019335366 A1 AU2019335366 A1 AU 2019335366A1
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
alkyl
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019335366A
Other languages
English (en)
Inventor
Lihu Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Birdie Biopharmaceuticals Inc Cayman Islands
Original Assignee
Birdie Biopharmaceuticals Inc Cayman Islands
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Birdie Biopharmaceuticals Inc Cayman Islands filed Critical Birdie Biopharmaceuticals Inc Cayman Islands
Publication of AU2019335366A1 publication Critical patent/AU2019335366A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2019335366A 2018-09-07 2019-09-05 Imidazoquinoline compounds and uses thereof Abandoned AU2019335366A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862728556P 2018-09-07 2018-09-07
US62/728,556 2018-09-07
PCT/US2019/049784 WO2020051356A1 (en) 2018-09-07 2019-09-05 Imidazoquinoline compounds and uses thereof

Publications (1)

Publication Number Publication Date
AU2019335366A1 true AU2019335366A1 (en) 2021-03-25

Family

ID=69722888

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019335366A Abandoned AU2019335366A1 (en) 2018-09-07 2019-09-05 Imidazoquinoline compounds and uses thereof

Country Status (9)

Country Link
US (1) US20210214354A1 (enExample)
EP (2) EP4306523A3 (enExample)
JP (1) JP2022501327A (enExample)
KR (1) KR20210074290A (enExample)
CN (1) CN113164460A (enExample)
AU (1) AU2019335366A1 (enExample)
CA (1) CA3111786A1 (enExample)
ES (1) ES2963112T3 (enExample)
WO (1) WO2020051356A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3092256T3 (da) 2014-01-10 2022-06-20 Birdie Biopharmaceuticals Inc Forbindelser og sammensætninger til immunterapi
CN121243402A (zh) 2014-07-09 2026-01-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1组合
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-egfr组合
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN109843327B (zh) 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
CA3067268A1 (en) 2017-06-23 2018-12-27 Birdie Biopharmaceuticals, Inc. Crystalline resiquimod monosulfate anhydrate and its preparation and uses
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
US20230248835A1 (en) * 2020-07-08 2023-08-10 Purdue Research Foundation Compounds, compositions, and methods for the treatment of fibrotic diseases and cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US689338A (en) * 1901-03-29 1901-12-17 Nat Faucet Company Tapping-bung.
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
JP2007504232A (ja) * 2003-09-05 2007-03-01 アナディス ファーマシューティカルズ インク Ｃ型肝炎ウイルス感染治療用のｔｌｒ７リガンド及びそのプロドラッグの投与
CN101056877B (zh) * 2004-09-14 2010-06-09 诺华疫苗和诊断公司 咪唑并喹啉化合物
US8728486B2 (en) * 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
US9034336B2 (en) * 2011-08-30 2015-05-19 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
PT3134402T (pt) * 2014-04-22 2020-07-02 Hoffmann La Roche Compostos de 4-amino-imidazoquinolina
CN121243402A (zh) * 2014-07-09 2026-01-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1组合
CN105233291A (zh) * 2014-07-09 2016-01-13 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
CN105732635A (zh) * 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 一类Toll样受体7激动剂
CN115350279A (zh) * 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合

Also Published As

Publication number Publication date
EP4306523A2 (en) 2024-01-17
JP2022501327A (ja) 2022-01-06
ES2963112T3 (es) 2024-03-25
EP4306523A3 (en) 2024-01-24
US20210214354A1 (en) 2021-07-15
EP3846807A4 (en) 2022-05-18
CN113164460A (zh) 2021-07-23
EP3846807A1 (en) 2021-07-14
WO2020051356A1 (en) 2020-03-12
EP3846807B1 (en) 2023-08-02
KR20210074290A (ko) 2021-06-21
CA3111786A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
EP3846807B1 (en) Imidazoquinoline compounds and uses thereof
US10968221B2 (en) Substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors
US10822349B2 (en) Macrocyclic purines for the treatment of viral infections
US10676457B2 (en) Cyclopropylamines as LSD1 inhibitors
TWI652269B (zh) 氮雜吡啶酮化合物及其用途
CN111606861A (zh) 用于治疗病毒感染和另外的疾病的酰氨基嘧啶衍生物
CN118843629A (zh) 抗病毒化合物及其制备和使用方法
EP4172142B1 (en) Branched lipid compounds
HK40101420A (en) Imidazoquinoline compounds and uses thereof
EP3067351B1 (en) Compound having higher inhibition of protein kinase g activity and preparation method therefor
HK40057163A (en) Imidazoquinoline compounds and uses thereof
HK40057163B (en) Imidazoquinoline compounds and uses thereof
US20240246978A1 (en) Phenyldihydropyrimidine compound and use thereof
WO2023168844A1 (zh) 氘代内酰胺类化合物及其制备方法、组合物和用途
CN116120254B (zh) 13,14-双一氧化氮供体-β-榄香烯衍生物及其制备和应用
CN117003771B (zh) 一种抗流感病毒衍生物及其用途
US20250353816A1 (en) Quinolines as modulators of polrmt
CN121941693A (zh) 化合物及其用途
CN114008029A (zh) 用于治疗病毒感染和另外的疾病的喹唑啉前药
HK40067856A (en) Quinazoline prodrugs for the treatment of viral infections and further diseases
HK40036815A (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application